Freedom Capital initiated coverage of LivaNova with a Hold rating and $81 price target. The neurostimulation market is an attractive growth opportunity where small-to-mid cap players like LivaNova can effectively carve out niches to dominate while the larger players focus on larger opportunities like chronic pain and movement disorders, says the analyst. However, the firm's near-to-mid-term expectations for organic sales growth in the mid-single digits and EBITDA growth in the high-single digits "appear priced in," the analyst added.
